## **Core Concept**
The question tests knowledge of antiretroviral drugs and their off-label uses, specifically in the context of treating chronic active hepatitis B infection. Hepatitis B and HIV can co-infect individuals, and certain drugs are effective against both viruses. The core concept here involves understanding the dual activity of certain antiretroviral agents against hepatitis B virus (HBV).

## **Why the Correct Answer is Right**
The correct answer, , is effective against both HIV and HBV. This drug belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs). It works by inhibiting the reverse transcriptase enzyme of HIV and the DNA polymerase of HBV, thereby reducing viral replication. This dual activity makes it a valuable option for treating patients co-infected with HIV and HBV.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is primarily used for treating HIV infection and certain types of cancer but is not known for its effectiveness against HBV.
- **Option B:** is another antiretroviral drug but does not have significant activity against HBV.
- **Option D:** is used in the treatment of HIV but lacks substantial efficacy against HBV.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for patients with chronic HBV infection, especially those co-infected with HIV, choosing an antiretroviral regimen that includes drugs active against HBV is crucial. This approach helps in managing both infections effectively and prevents the development of resistance.

## **Correct Answer:** . Lamivudine.